Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle.

Welch RD, Billon C, Valfort AC, Burris TP, Flaveny CA.

Sci Rep. 2017 Dec 7;7(1):17142. doi: 10.1038/s41598-017-17496-7.

2.

Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome.

Welch RD, Guo C, Sengupta M, Carpenter KJ, Stephens NA, Arnett SA, Meyers MJ, Sparks LM, Smith SR, Zhang J, Burris TP, Flaveny CA.

Mol Metab. 2017 May 19;6(7):703-714. doi: 10.1016/j.molmet.2017.05.001. eCollection 2017 Jul.

3.

REV-ERB and ROR: therapeutic targets for treating myopathies.

Welch RD, Flaveny CA.

Phys Biol. 2017 Jun 6;14(4):045002. doi: 10.1088/1478-3975/14/4/045002. Review.

PMID:
28586319
4.

Fluorophore-NanoLuc BRET Reporters Enable Sensitive In Vivo Optical Imaging and Flow Cytometry for Monitoring Tumorigenesis.

Schaub FX, Reza MS, Flaveny CA, Li W, Musicant AM, Hoxha S, Guo M, Cleveland JL, Amelio AL.

Cancer Res. 2015 Dec 1;75(23):5023-33. doi: 10.1158/0008-5472.CAN-14-3538. Epub 2015 Sep 30.

5.

Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.

Flaveny CA, Griffett K, El-Gendy Bel-D, Kazantzis M, Sengupta M, Amelio AL, Chatterjee A, Walker J, Solt LA, Kamenecka TM, Burris TP.

Cancer Cell. 2015 Jul 13;28(1):42-56. doi: 10.1016/j.ccell.2015.05.007. Epub 2015 Jun 25.

6.

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis.

Griffett K, Welch RD, Flaveny CA, Kolar GR, Neuschwander-Tetri BA, Burris TP.

Mol Metab. 2015 Feb 9;4(4):353-7. doi: 10.1016/j.molmet.2015.01.009. eCollection 2015 Apr.

7.

Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis.

Li B, Flaveny CA, Giambelli C, Fei DL, Han L, Hang BI, Bai F, Pei XH, Nose V, Burlingame O, Capobianco AJ, Orton D, Lee E, Robbins DJ.

PLoS One. 2014 Jul 8;9(7):e101969. doi: 10.1371/journal.pone.0101969. eCollection 2014.

8.

Pyrvinium attenuates Hedgehog signaling downstream of smoothened.

Li B, Fei DL, Flaveny CA, Dahmane N, Baubet V, Wang Z, Bai F, Pei XH, Rodriguez-Blanco J, Hang B, Orton D, Han L, Wang B, Capobianco AJ, Lee E, Robbins DJ.

Cancer Res. 2014 Sep 1;74(17):4811-21. doi: 10.1158/0008-5472.CAN-14-0317. Epub 2014 Jul 3.

9.

Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3',4'-dimethoxy-α-naphthoflavone.

Murray IA, Flaveny CA, Chiaro CR, Sharma AK, Tanos RS, Schroeder JC, Amin SG, Bisson WH, Kolluri SK, Perdew GH.

Mol Pharmacol. 2011 Mar;79(3):508-19. doi: 10.1124/mol.110.069369. Epub 2010 Dec 2.

10.

Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.

Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, Walker JR, Flaveny CA, Perdew GH, Denison MS, Schultz PG, Cooke MP.

Science. 2010 Sep 10;329(5997):1345-8. doi: 10.1126/science.1191536. Epub 2010 Aug 5. Erratum in: Science. 2011 May 6;332(6030):664.

11.

Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling.

DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, Omiecinski CJ, Perdew GH.

Toxicol Sci. 2010 May;115(1):89-97. doi: 10.1093/toxsci/kfq024. Epub 2010 Jan 27.

12.

Differential gene regulation by the human and mouse aryl hydrocarbon receptor.

Flaveny CA, Murray IA, Perdew GH.

Toxicol Sci. 2010 Apr;114(2):217-25. doi: 10.1093/toxsci/kfp308. Epub 2009 Dec 31.

13.

The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor.

Schroeder JC, Dinatale BC, Murray IA, Flaveny CA, Liu Q, Laurenzana EM, Lin JM, Strom SC, Omiecinski CJ, Amin S, Perdew GH.

Biochemistry. 2010 Jan 19;49(2):393-400. doi: 10.1021/bi901786x.

14.

Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity.

Murray IA, Morales JL, Flaveny CA, Dinatale BC, Chiaro C, Gowdahalli K, Amin S, Perdew GH.

Mol Pharmacol. 2010 Feb;77(2):247-54. doi: 10.1124/mol.109.061788. Epub 2009 Nov 10.

15.

Antagonism of aryl hydrocarbon receptor signaling by 6,2',4'-trimethoxyflavone.

Murray IA, Flaveny CA, DiNatale BC, Chairo CR, Schroeder JC, Kusnadi A, Perdew GH.

J Pharmacol Exp Ther. 2010 Jan;332(1):135-44. doi: 10.1124/jpet.109.158261. Epub 2009 Oct 14. Erratum in: J Pharmacol Exp Ther. 2018 Nov;367(2):291.

16.

Ah receptor represses acute-phase response gene expression without binding to its cognate response element.

Patel RD, Murray IA, Flaveny CA, Kusnadi A, Perdew GH.

Lab Invest. 2009 Jun;89(6):695-707. doi: 10.1038/labinvest.2009.24. Epub 2009 Mar 30.

17.

Ligand selectivity and gene regulation by the human aryl hydrocarbon receptor in transgenic mice.

Flaveny CA, Murray IA, Chiaro CR, Perdew GH.

Mol Pharmacol. 2009 Jun;75(6):1412-20. doi: 10.1124/mol.109.054825. Epub 2009 Mar 19.

18.

Supplemental Content

Loading ...
Support Center